Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038)
Year: 2017
Type: article
Source: European Journal of Cancer
Authors: S. Sadeghi, S. Groshen, R. Parikh, A. Mortazavi, T. Dorff, C. Hoimes, S. Pal, E. Levine, L. Doyle, D. Quinn, E. Newman, P. Lara
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2586681119